- Home
- PAYO vs PTGX Comparison
PAYO vs PTGX Comparison
Compare PAYO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- PTGX
- Stock Information
- Founded
- PAYO 2005
- PTGX 2006
- Country
- PAYO United States
- PTGX United States
- Employees
- PAYO N/A
- PTGX N/A
- Industry
- PAYO EDP Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- PTGX Health Care
- Exchange
- PAYO Nasdaq
- PTGX Nasdaq
- Market Cap
- PAYO 3.2B
- PTGX 2.8B
- IPO Year
- PAYO N/A
- PTGX 2016
- Fundamental
- Price
- PAYO $8.66
- PTGX $47.91
- Analyst Decision
- PAYO Strong Buy
- PTGX Strong Buy
- Analyst Count
- PAYO 7
- PTGX 7
- Target Price
- PAYO $8.93
- PTGX $52.83
- AVG Volume (30 Days)
- PAYO 2.0M
- PTGX 450.1K
- Earning Date
- PAYO 11-05-2024
- PTGX 11-08-2024
- Dividend Yield
- PAYO N/A
- PTGX N/A
- EPS Growth
- PAYO 447.53
- PTGX N/A
- EPS
- PAYO 0.26
- PTGX 2.75
- Revenue
- PAYO $900,058,000.00
- PTGX $319,120,000.00
- Revenue This Year
- PAYO $14.06
- PTGX $400.33
- Revenue Next Year
- PAYO $7.49
- PTGX N/A
- P/E Ratio
- PAYO $32.93
- PTGX $17.54
- Revenue Growth
- PAYO 21.43
- PTGX 125.73
- 52 Week Low
- PAYO $4.22
- PTGX $13.76
- 52 Week High
- PAYO $8.60
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- PAYO 81.47
- PTGX 60.40
- Support Level
- PAYO $8.27
- PTGX $45.33
- Resistance Level
- PAYO $8.56
- PTGX $48.89
- Average True Range (ATR)
- PAYO 0.16
- PTGX 1.28
- MACD
- PAYO 0.02
- PTGX 0.11
- Stochastic Oscillator
- PAYO 100.00
- PTGX 77.11
About PAYO Payoneer Global Inc.
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.